Cancer Immunology – News and Features

News
Isarna Therapeutics Raises Euro 13 Million from New and Current Investors
Euro 13 million raised in equity from AT NewTec and MIG-managed funds.

News
Stellar Issues Year-End Results and Highlights from 2013
Company announces financial results and operational highlights for 2013.

News
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.

News
Stellar Announces Collaboration with Amaran Biotechnology, Inc.
Collaboration agreement to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy.

News
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.

News
Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.

News
Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune announces that study continues to report encouraging response rates, safety and proof of mechanism.

News
Agalimmune Founded to Develop Immunotherapeutics for Cancer
Funding will be used to continue the translation of Alphaject™ licensed from UMMS.

News
Study Finds Gut Microorganisms May Determine Cancer Treatment Outcome
An intact population of microorganisms that derive food and benefit from other organisms living in the intestine is required for optimal response to cancer therapy.

News
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Advertisement